198481-33-3 | Bazedoxifene acetate

Packsize	Purity	Availability	Price	Discounted Price
5mg	95%	in stock	$143.00	$100.00
250mg	95%	in stock	$200.00	$140.00
1g	95%	in stock	$484.00	$339.00
5g	95%	in stock	$1,535.00	$1,074.00

Description

• Catalog Number: AB08075
• Chemical Name: Bazedoxifene acetate
• CAS Number: 198481-33-3
• Molecular Formula: C32H38N2O5
• Molecular Weight: 530.6545
• MDL Number: MFCD09260074
• SMILES: Oc1ccc2c(c1)c(C)c(n2Cc1ccc(cc1)OCCN1CCCCCC1)c1ccc(cc1)O.CC(=O)O

Computed Properties

• Complexity: 654
• Covalently-Bonded Unit Count: 2
• Heavy Atom Count: 39
• Hydrogen Bond Acceptor Count: 6
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 7

Literature

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• The evolution of selective estrogen receptor modulators in osteoporosis therapy.

  Climacteric : the journal of the International Menopause Society 20121201

• Relationships between changes in bone mineral density or bone turnover markers and vertebral fracture incidence in patients treated with bazedoxifene.

  Calcified tissue international 20121001

• The tissue selective estrogen complex: a novel approach to the treatment of menopausal symptoms.

  Journal of women's health (2002) 20120901

• Future long-term trials of postmenopausal hormone replacement therapy - what is possible and what is the optimal protocol and regimen?

  Climacteric : the journal of the International Menopause Society 20120601

• [New approved drugs for osteoporosis in Japan].

  Clinical calcium 20120601

• In vitro bioactivation of bazedoxifene and 2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol in human liver microsomes.

  Chemico-biological interactions 20120415

• Using bazedoxifene plus conjugated estrogens for treating postmenopausal women: a comprehensive review.

  Menopause (New York, N.Y.) 20120401

• Bazedoxifene: a guide to its use in postmenopausal osteoporosis.

  Drugs & aging 20120401

• An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosis.

  Maturitas 20120301

• Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120101

• The effects of 17β-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis.

  Gynecologic oncology 20120101

• Bazedoxifene: a review of its use in the treatment of postmenopausal osteoporosis.

  Drugs 20111112

• The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor α and cyclin D1.

  Molecular pharmacology 20111001

• Bone: in search of the perfect SERM--a 5-year study of bazedoxifene.

  Nature reviews. Endocrinology 20110920

• Tissue-selective estrogen complex bazedoxifene and conjugated estrogens for the treatment of menopausal vasomotor symptoms.

  Drugs 20110910

• Skeletal effects of bazedoxifene paired with conjugated estrogens in ovariectomized rats.

  Bone 20110901

• Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse model.

  Endocrinology 20110801

• Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.

  Journal of medicinal chemistry 20110714

• [Diagnostic imaging of treatment in osteoporosis: SERM].

  Clinical calcium 20110701

• Selective estrogen receptor modulators: the future in menopausal treatment.

  Minerva ginecologica 20110601

• [Selective estrogen receptor modulators: focus on bazedoxifene].

  Minerva ginecologica 20110601

• Bazedoxifene: a new selective estrogen receptor modulator for postmenopausal osteoporosis.

  Menopause international 20110601

• Effects of bazedoxifene in nonflushing postmenopausal women: a randomized phase 2 trial.

  Menopause (New York, N.Y.) 20110501

• Treating menopausal symptoms with a tissue-selective estrogen complex.

  Gender medicine 20110401

• Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110301

• Effects of bazedoxifene on bone mineral density, bone turnover, and safety in postmenopausal Japanese women with osteoporosis.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20110301

• Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110201

• Efficacy and safety of bazedoxifene in postmenopausal Asian women.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110201

• Preventing osteoporosis with a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens (BZA/CE).

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110201

• The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women.

  Menopause (New York, N.Y.) 20110101

• [Bazedoxifene as a new-generation SERM].

  Clinical calcium 20110101

• Efficacy and safety of bazedoxifene for postmenopausal osteoporosis.

  Clinical interventions in aging 20110101

• Binding capacity of ER-α ligands and SERMs: comparison of the human, dog and cat.

  Asian Pacific journal of cancer prevention : APJCP 20110101

• Bazedoxifene when paired with conjugated estrogens is a new paradigm for treatment of postmenopausal women.

  Expert opinion on investigational drugs 20101201

• Third-generation SERMs may face uphill battle.

  Journal of the National Cancer Institute 20101117

• In vitro metabolism, permeability, and efflux of bazedoxifene in humans.

  Drug metabolism and disposition: the biological fate of chemicals 20100901

• New selective estrogen receptor modulators (SERMs) in development.

  Current osteoporosis reports 20100901

• Tissue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex.

  Menopause international 20100901

• FRAX and its applications in health economics--cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example.

  Bone 20100801

• Disposition of bazedoxifene in rats.

  Xenobiotica; the fate of foreign compounds in biological systems 20100801

• Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.

  Current medical research and opinion 20100701

• Bazedoxifene: a novel selective estrogen receptor modulator for postmenopausal osteoporosis.

  Climacteric : the journal of the International Menopause Society 20100601

• Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy.

  Climacteric : the journal of the International Menopause Society 20100401

• An innovative method to classify SERMs based on the dynamics of estrogen receptor transcriptional activity in living animals.

  Molecular endocrinology (Baltimore, Md.) 20100401

• Aprela, a single tablet formulation of bazedoxifene and conjugated equine estrogens (Premarin) for the potential treatment of menopausal symptoms.

  Current opinion in investigational drugs (London, England : 2000) 20100401

• Selective estrogen receptor modulators decrease the production of interleukin-6 and interferon-gamma-inducible protein-10 by astrocytes exposed to inflammatory challenge in vitro.

  Glia 20100101

• Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens.

  The Journal of steroid biochemistry and molecular biology 20100101

• Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis.

  BMC musculoskeletal disorders 20100101

• Cross-geographic region differences in quality of life in women with and without vertebral fracture.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20091001

• Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis.

  Journal of women's health (2002) 20091001

• Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy.

  Fertility and sterility 20090901

• Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women.

  Fertility and sterility 20090901

• Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile.

  Fertility and sterility 20090901

• Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women.

  Fertility and sterility 20090901

• New therapies for osteoporosis: zoledronic acid, bazedoxifene, and denosumab.

  Current osteoporosis reports 20090901

• Bazedoxifene acetate: a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.

  Drugs of today (Barcelona, Spain : 1998) 20090701

• Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.

  Bone 20090601

• Metabolic disposition of [14C]bazedoxifene in healthy postmenopausal women.

  Drug metabolism and disposition: the biological fate of chemicals 20090601

• Bazedoxifene: a new selective estrogen receptor modulator for the treatment of postmenopausal osteoporosis.

  Expert opinion on pharmacotherapy 20090601

• Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland.

  Endocrinology 20090401

• The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis.

  Menopause (New York, N.Y.) 20090101

• Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women.

  Menopause (New York, N.Y.) 20090101

• Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis.

  Menopause (New York, N.Y.) 20090101

• Altering the propensity for density: the benefits and risks of selective estrogen receptor modulators.

  Menopause (New York, N.Y.) 20090101

• Clinical issues regarding cardiovascular disease and selective estrogen receptor modulators in postmenopausal women.

  Climacteric : the journal of the International Menopause Society 20090101

• Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20081201

• The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention.

  Endocrinology 20081201

• [Newly developed drugs for osteoporosis in overseas and their future roles for the therapy].

  Clinical calcium 20081001

• Bazedoxifene: a selective estrogen-receptor modulator.

  Women's health (London, England) 20080701

• Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary gland.

  Molecular and cellular endocrinology 20080611

• Bazedoxifene: bazedoxifene acetate, TSE 424, TSE-424, WAY 140424.

  Drugs in R&D 20080101

• [Status of novel bone-targeting SERMs in development].

  Nihon rinsho. Japanese journal of clinical medicine 20071128

• Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis.

  Expert opinion on investigational drugs 20071001

• Update on bazedoxifene: a novel selective estrogen receptor modulator.

  Clinical interventions in aging 20070901

• Bazedoxifene: a third-generation selective estrogen receptor modulator for treatment of postmenopausal osteoporosis.

  The Annals of pharmacotherapy 20070501

• [Therapeutic agents for disorders of bone and calcium metabolism: Bazedoxifene].

  Clinical calcium 20070101

• [Next generation selective estrogen receptor modulators].

  Clinical calcium 20060101

• Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity.

  Endocrinology 20050901

• Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women.

  Obstetrics and gynecology 20050601

• Bazedoxifene (Wyeth).

  Current opinion in investigational drugs (London, England : 2000) 20041001

• Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation.

  Annals of the New York Academy of Sciences 20011201

• Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination.

  Molecular endocrinology (Baltimore, Md.)